JD Health (6618, 86618) Schedules Board Meeting on March 5, 2026 to Discuss 2025 Annual Results

Bulletin Express
Feb 20

JD Health International Inc. (“JD Health”), with stock codes 6618 (HKD counter) and 86618 (RMB counter), plans to hold a Board meeting on Thursday, March 5, 2026. The meeting will address the annual results for the year ended December 31, 2025 and consider a final dividend distribution, if any.

A conference call will be held at 5:00 pm (Beijing/Hong Kong Time) on the same day to discuss these results. Participants are advised to dial in at least 10 minutes before the scheduled start time. The dial-in numbers are as follows: Mainland China 400 810 8228 (Mandarin)/400 810 8128 (English), Hong Kong +852 3005 1355 (Mandarin)/+852 3005 1313 (English), U.S. +1 6462543594, Singapore +65 68185374. The Mandarin Channel Participant Code is 187150, and the English Channel Participant Code is 611787. Further global dial-in information is accessible via the provided online link.

According to the announcement dated February 20, 2026, the Board comprises one executive Director, one non-executive Director, and five independent non-executive Directors. The executive Director is Mr. Dong Cao, the non-executive Director is Mr. Richard Qiangdong Liu, and the independent non-executive Directors are Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen, Mr. Ying Wu, and Professor George Lau.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10